Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

BMS And AstraZeneca Diabetes Drug Reduces HbA1c

September 20, 2010 8:10 am | News | Comments

Bristol-Myers Squibb Company and AstraZeneca announced that a randomized, double blind Phase 3 clinical study demonstrated that the addition of dapagliflozin to existing glimepiride therapy produced significant reductions in HbA1c in adult patients with type 2 diabetes compared to glimepiride alone.


Harbor BioSciences Recieves Triolex Patent

September 20, 2010 8:05 am | News | Comments

Harbor BioSciences, Inc. announced that the company has received patent No. 7,776,845 from the United States Patent and Trademark Office which covers its lead metabolic disease and anti-inflammation drug candidate Triolex (HE3286).


FDA Explores Actos Cancer Link

September 20, 2010 8:02 am | by Matthew Perrone | News | Comments

The Food and Drug Administration is reviewing data suggesting a possible link between the widely used diabetes medication Actos and bladder cancer.


Spirivia As Good As Serevent

September 20, 2010 8:00 am | by Alicia Chang | News | Comments

Researchers say they've found a possible new treatment for adults with hard-to-control asthma. Their discovery, however, came at a price.


CEDRA Corporation Changes Name

September 20, 2010 7:51 am | News | Comments

Operating as a division of Worldwide Clinical Trials over the past three years, CEDRA Corporation announces its new company name, Worldwide Clinical Trials Drug Development Solutions.


Finding the Right Formula

September 20, 2010 7:22 am | by Rita C. Peters, Editorial Director | Articles | Comments

Like other sectors of the drug discovery and development process, drug formulation and drug delivery research has been challenged with finding effective and economical routes to bringing a drug to its target.


Scintillation Cocktail

September 17, 2010 9:07 am | Product Releases | Comments

SafeScint 1:1 from LabLogic Systems is a scintillation cocktail for discrete sample counting with a biodegradable formulation and outstanding counting efficiency with a high sample uptake capacity that saves on both consumption and disposal.


Rapid Microbiology System

September 17, 2010 9:04 am | Product Releases | Comments

Pall Corporation announced the introduction of the GeneDisc Rapid Microbiology System for advanced microbial quality monitoring. This system represents Pall’s latest quality assurance innovation for the pharmaceutical manufacturing industry.


CDI Partnering With ACEA on Cardiotoxicity

September 17, 2010 8:54 am | News | Comments

Cellular Dynamics International (CDI) announced their partnership with ACEA Biosciences to bring early and accurate prediction of potential cardiotoxic side effects to the drug discovery process.


Head of Recall-Plagued J & J Division Resigns

September 17, 2010 8:51 am | by Linda A. Johnson | News | Comments

The head of the Johnson & Johnson division responsible for most of the company's 11 product recalls announced her retirement, shortly after a congressional committee probing the recalls invited her to a second hearing on the case.


GSK to Focus on Subcutaneous Delivery of Ofatumumab

September 17, 2010 8:46 am | News | Comments

After review of the program's full development strategy, GSK will focus development efforts on the subcutaneous delivery of ofatumumab in autoimmune indications and will stop further development work on the intravenous route of administration in autoimmune disease.


Scripps Researching Next-Gen DNA Sequencing

September 17, 2010 8:39 am | News | Comments

Scripps Research Institute has been awarded grant by the National Institutes of Health to help develop the next generation of DNA sequencing technologies, which could enable biomedical researchers and health care workers to routinely sequence a person’s DNA.


Bacteria May Lead to IBD in Some

September 17, 2010 8:34 am | News | Comments

Certain bacteria that inhabit the intestine provide the environmental trigger that initiates and perpetuates chronic intestinal inflammation in individuals who are genetically susceptible to inflammatory bowel disease (IBD), a study has found.


Fat Stem Cells Safe for Rebuilding In Absence of Cancer

September 17, 2010 8:25 am | News | Comments

Fat-derived stem cells can be safely used to aid reconstruction of breast tissue after mastectomy as long as there is no evidence of active cancer, according to researchers at the University of Pittsburgh School of Medicine.


New Genomic Analysis Tracks Kidney Damaging Gene

September 17, 2010 8:23 am | News | Comments

A University of Michigan-led research team has identified a gene responsible in some families for a devastating inherited kidney disorder, thanks to a new, faster method of genetic analysis not available even two years ago.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.